Wet, Wet, Wet
Continuous wet granulation will be the star of a new UK facility, which stems from a collaboration between CPI, GSK and AstraZeneca.
Stephanie Sutton |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques.
In the UK, CPI is collaborating with GlaxoSmithKline and AstraZeneca to establish a small-scale continuous wet granulation manufacturing facility for oral solid dosage forms. The facility is due to be completed in Q3 2020 and will be available as a national, open-access centre for contract development. The facility is part of a project called PROSPECT CP (Proving Real-world Scalable Predictive Tools/Technologies for Complex Particles).
“One of CPI’s strategic themes is predictive design and manufacturability, which includes exploring the use of PAT-enabled, model-based process control to help speed the adoption of digital manufacturing technologies across the whole formulation industry,” says Jacquin Wilford-Brown, Principal Scientist at CPI. “PROSPECT CP is one component of this, seeking to create a facility to remove risks and barriers, and speed up development of new solid products. The initial demonstrator is in the pharmaceutical space, building on our previous work and linking forward to the Medicines Manufacturing Innovation Centre.”
Tablets remain the most prevalent drug delivery method and wet granulation is often used for APIs with challenging processing properties, as some molecules are simply not amenable to direct compression approaches. In recent years, CPI has noted that more and more pharma companies are expressing interest in continuous technologies. Given that the UK Medicines Manufacturing Innovation Centre is running a project focused on direct compression, it made sense for CPI and its partners to look at twin-screw wet granulation.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.